Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 65 entries
Sorted by: Best Match Show Resources per page
Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability.

Frontiers in pharmacology

Barbieri F, Würth R, Pattarozzi A, Verduci I, Mazzola C, Cattaneo MG, Tonelli M, Solari A, Bajetto A, Daga A, Vicentini LM, Mazzanti M, Florio T.
PMID: 30186163
Front Pharmacol. 2018 Aug 21;9:899. doi: 10.3389/fphar.2018.00899. eCollection 2018.

The antidiabetic biguanide metformin exerts antiproliferative effects in different solid tumors. However, during preclinical studies, metformin concentrations required to induce cell growth arrest were invariably within the mM range, thus difficult to translate in a clinical setting. Consequently, the...

Cite
Barbieri F, Würth R, Pattarozzi A, et al. Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability. Front Pharmacol. 2018;9:899doi: 10.3389/fphar.2018.00899.
Barbieri, F., Würth, R., Pattarozzi, A., Verduci, I., Mazzola, C., Cattaneo, M. G., Tonelli, M., Solari, A., Bajetto, A., Daga, A., Vicentini, L. M., Mazzanti, M., & Florio, T. (2018). Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability. Frontiers in pharmacology, 9899. https://doi.org/10.3389/fphar.2018.00899
Barbieri, Federica, et al. "Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability." Frontiers in pharmacology vol. 9 (2018): 899. doi: https://doi.org/10.3389/fphar.2018.00899
Barbieri F, Würth R, Pattarozzi A, Verduci I, Mazzola C, Cattaneo MG, Tonelli M, Solari A, Bajetto A, Daga A, Vicentini LM, Mazzanti M, Florio T. Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability. Front Pharmacol. 2018 Aug 21;9:899. doi: 10.3389/fphar.2018.00899. eCollection 2018. PMID: 30186163; PMCID: PMC6110922.
Copy Download .nbib Format: NLM
Metabolic Profiles Associated With Metformin Efficacy in Cancer.

Frontiers in endocrinology

Andrzejewski S, Siegel PM, St-Pierre J.
PMID: 30186229
Front Endocrinol (Lausanne). 2018 Aug 21;9:372. doi: 10.3389/fendo.2018.00372. eCollection 2018.

Metformin is one of the most commonly prescribed medications for the treatment of type 2 diabetes. Numerous reports have suggested potential anti-cancerous and cancer preventive properties of metformin, although these findings vary depending on the intrinsic properties of the...

Cite
Andrzejewski S, Siegel PM, St-Pierre J. Metabolic Profiles Associated With Metformin Efficacy in Cancer. Front Endocrinol (Lausanne). 2018;9:372doi: 10.3389/fendo.2018.00372.
Andrzejewski, S., Siegel, P. M., & St-Pierre, J. (2018). Metabolic Profiles Associated With Metformin Efficacy in Cancer. Frontiers in endocrinology, 9372. https://doi.org/10.3389/fendo.2018.00372
Andrzejewski, Sylvia, et al. "Metabolic Profiles Associated With Metformin Efficacy in Cancer." Frontiers in endocrinology vol. 9 (2018): 372. doi: https://doi.org/10.3389/fendo.2018.00372
Andrzejewski S, Siegel PM, St-Pierre J. Metabolic Profiles Associated With Metformin Efficacy in Cancer. Front Endocrinol (Lausanne). 2018 Aug 21;9:372. doi: 10.3389/fendo.2018.00372. eCollection 2018. PMID: 30186229; PMCID: PMC6110930.
Copy Download .nbib Format: NLM
[How to differentiate between useful and useless drugs?].

La Revue du praticien

Bergmann JF, Thervet E, Timsit J, Blacher J, Varet B, Hartemann A, Chosidow O, Mariette X, Gervais A, Amoura Z, Bruckert E, Pariente A, Vernant JP, Penformis F, Dautzenberg B, Sobel A, Guillevin L, Valla D, Leblond V, Gaudric A, Chast F, Bourdillon F, Fredenrich A, Bourgeois P, Grimaldi A.
PMID: 23272464
Rev Prat. 2012 Nov;62(9):1192-5.

No abstract available.

Cite
Bergmann JF, Thervet E, Timsit J, et al. Comment différencier les médicaments utiles et inutiles. [How to differentiate between useful and useless drugs?]. Rev Prat. 2012;62(9):1192-5
Bergmann, J. F., Thervet, E., Timsit, J., Blacher, J., Varet, B., Hartemann, A., Chosidow, O., Mariette, X., Gervais, A., Amoura, Z., Bruckert, E., Pariente, A., Vernant, J. P., Penformis, F., Dautzenberg, B., Sobel, A., Guillevin, L., Valla, D., Leblond, V., Gaudric, A., Chast, F., Bourdillon, F., Fredenrich, A., Bourgeois, P., & Grimaldi, A. (2012). Comment différencier les médicaments utiles et inutiles. [How to differentiate between useful and useless drugs?]. La Revue du praticien, 62(9), 1192-5.
Bergmann, Jean-François, et al. "Comment différencier les médicaments utiles et inutiles." [How to differentiate between useful and useless drugs?]. La Revue du praticien vol. 62,9 (2012): 1192-5.
Bergmann JF, Thervet E, Timsit J, Blacher J, Varet B, Hartemann A, Chosidow O, Mariette X, Gervais A, Amoura Z, Bruckert E, Pariente A, Vernant JP, Penformis F, Dautzenberg B, Sobel A, Guillevin L, Valla D, Leblond V, Gaudric A, Chast F, Bourdillon F, Fredenrich A, Bourgeois P, Grimaldi A. Comment différencier les médicaments utiles et inutiles. [How to differentiate between useful and useless drugs?]. Rev Prat. 2012 Nov;62(9):1192-5. French. PMID: 23272464.
Copy Download .nbib Format: NLM
Defining the short-term effects of pharmacological 5'-AMP activated kinase modulators on mitochondrial polarization, morphology and heterogeneity.

PeerJ

Kodiha M, Flamant E, Wang YM, Stochaj U.
PMID: 30186684
PeerJ. 2018 Aug 30;6:e5469. doi: 10.7717/peerj.5469. eCollection 2018.

BACKGROUND: Under aerobic growth conditions, mitochondria are the major producers of cellular ATP and crucial for the proper performance of organs and tissues. This applies especially to cells with high energy demand, such as the renal proximal tubule epithelium....

Cite
Kodiha M, Flamant E, Wang YM, et al. Defining the short-term effects of pharmacological 5'-AMP activated kinase modulators on mitochondrial polarization, morphology and heterogeneity. PeerJ. 2018;6:e5469doi: 10.7717/peerj.5469.
Kodiha, M., Flamant, E., Wang, Y. M., & Stochaj, U. (2018). Defining the short-term effects of pharmacological 5'-AMP activated kinase modulators on mitochondrial polarization, morphology and heterogeneity. PeerJ, 6e5469. https://doi.org/10.7717/peerj.5469
Kodiha, Mohamed, et al. "Defining the short-term effects of pharmacological 5'-AMP activated kinase modulators on mitochondrial polarization, morphology and heterogeneity." PeerJ vol. 6 (2018): e5469. doi: https://doi.org/10.7717/peerj.5469
Kodiha M, Flamant E, Wang YM, Stochaj U. Defining the short-term effects of pharmacological 5'-AMP activated kinase modulators on mitochondrial polarization, morphology and heterogeneity. PeerJ. 2018 Aug 30;6:e5469. doi: 10.7717/peerj.5469. eCollection 2018. PMID: 30186684; PMCID: PMC6119600.
Copy Download .nbib Format: NLM
Glucoregulatory and Anti-Inflammatory Activities of Peptide Fractions Separated by Electrodialysis with Ultrafiltration Membranes from Salmon Protein Hydrolysate and Identification of Four Novel Glucoregulatory Peptides.

Membranes

Henaux L, Pereira KD, Thibodeau J, Pilon G, Gill T, Marette A, Bazinet L.
PMID: 34357178
Membranes (Basel). 2021 Jul 14;11(7). doi: 10.3390/membranes11070528.

Natural bioactive peptides are suitable candidates for preventing the development of Type 2 diabetes (T2D), by reducing the various risk factors. The aim of this study was to concentrate glucoregulatory and anti-inflammatory peptides, from salmon by-products, by electrodialysis with...

Cite
Henaux L, Pereira KD, Thibodeau J, et al. Glucoregulatory and Anti-Inflammatory Activities of Peptide Fractions Separated by Electrodialysis with Ultrafiltration Membranes from Salmon Protein Hydrolysate and Identification of Four Novel Glucoregulatory Peptides. Membranes (Basel). 2021;11(7)doi: 10.3390/membranes11070528.
Henaux, L., Pereira, K. D., Thibodeau, J., Pilon, G., Gill, T., Marette, A., & Bazinet, L. (2021). Glucoregulatory and Anti-Inflammatory Activities of Peptide Fractions Separated by Electrodialysis with Ultrafiltration Membranes from Salmon Protein Hydrolysate and Identification of Four Novel Glucoregulatory Peptides. Membranes, 11(7), . https://doi.org/10.3390/membranes11070528
Henaux, Loïc, et al. "Glucoregulatory and Anti-Inflammatory Activities of Peptide Fractions Separated by Electrodialysis with Ultrafiltration Membranes from Salmon Protein Hydrolysate and Identification of Four Novel Glucoregulatory Peptides." Membranes vol. 11,7 (2021). doi: https://doi.org/10.3390/membranes11070528
Henaux L, Pereira KD, Thibodeau J, Pilon G, Gill T, Marette A, Bazinet L. Glucoregulatory and Anti-Inflammatory Activities of Peptide Fractions Separated by Electrodialysis with Ultrafiltration Membranes from Salmon Protein Hydrolysate and Identification of Four Novel Glucoregulatory Peptides. Membranes (Basel). 2021 Jul 14;11(7). doi: 10.3390/membranes11070528. PMID: 34357178; PMCID: PMC8305187.
Copy Download .nbib Format: NLM
Metabolic determinants of cellular fitness dependent on mitochondrial reactive oxygen species.

Science advances

Kong H, Reczek CR, McElroy GS, Steinert EM, Wang T, Sabatini DM, Chandel NS.
PMID: 33148642
Sci Adv. 2020 Nov 04;6(45). doi: 10.1126/sciadv.abb7272. Print 2020 Nov.

Mitochondria-derived reactive oxygen species (mROS) are required for the survival, proliferation, and metastasis of cancer cells. The mechanism by which mitochondrial metabolism regulates mROS levels to support cancer cells is not fully understood. To address this, we conducted a...

Cite
Kong H, Reczek CR, McElroy GS, et al. Metabolic determinants of cellular fitness dependent on mitochondrial reactive oxygen species. Sci Adv. 2020;6(45)doi: 10.1126/sciadv.abb7272.
Kong, H., Reczek, C. R., McElroy, G. S., Steinert, E. M., Wang, T., Sabatini, D. M., & Chandel, N. S. (2020). Metabolic determinants of cellular fitness dependent on mitochondrial reactive oxygen species. Science advances, 6(45), . https://doi.org/10.1126/sciadv.abb7272
Kong, Hyewon, et al. "Metabolic determinants of cellular fitness dependent on mitochondrial reactive oxygen species." Science advances vol. 6,45 (2020). doi: https://doi.org/10.1126/sciadv.abb7272
Kong H, Reczek CR, McElroy GS, Steinert EM, Wang T, Sabatini DM, Chandel NS. Metabolic determinants of cellular fitness dependent on mitochondrial reactive oxygen species. Sci Adv. 2020 Nov 04;6(45). doi: 10.1126/sciadv.abb7272. Print 2020 Nov. PMID: 33148642; PMCID: PMC7673681.
Copy Download .nbib Format: NLM
Phenformin and ataxia-telangiectasia mutated inhibitors synergistically co-suppress liver cancer cell growth by damaging mitochondria.

FEBS open bio

Wu T, Zhou S, Qin M, Tang J, Yan X, Huang L, Huang M, Deng J, Xiao D, Hu X, Wu J, Yang X, Li G.
PMID: 33742560
FEBS Open Bio. 2021 May;11(5):1440-1451. doi: 10.1002/2211-5463.13152. Epub 2021 Apr 03.

Inhibitors of ataxia-telangiectasia mutated (ATM), such as KU-55933 (Ku), represent a promising class of novel anticancer drugs. In addition, the biguanide derivative phenformin exhibits antitumor activity superior to that of the AMPK activator metformin. Herein, we assessed the potential...

Cite
Wu T, Zhou S, Qin M, et al. Phenformin and ataxia-telangiectasia mutated inhibitors synergistically co-suppress liver cancer cell growth by damaging mitochondria. FEBS Open Bio. 2021;11(5):1440-1451doi: 10.1002/2211-5463.13152.
Wu, T., Zhou, S., Qin, M., Tang, J., Yan, X., Huang, L., Huang, M., Deng, J., Xiao, D., Hu, X., Wu, J., Yang, X., & Li, G. (2021). Phenformin and ataxia-telangiectasia mutated inhibitors synergistically co-suppress liver cancer cell growth by damaging mitochondria. FEBS open bio, 11(5), 1440-1451. https://doi.org/10.1002/2211-5463.13152
Wu, Tianyu, et al. "Phenformin and ataxia-telangiectasia mutated inhibitors synergistically co-suppress liver cancer cell growth by damaging mitochondria." FEBS open bio vol. 11,5 (2021): 1440-1451. doi: https://doi.org/10.1002/2211-5463.13152
Wu T, Zhou S, Qin M, Tang J, Yan X, Huang L, Huang M, Deng J, Xiao D, Hu X, Wu J, Yang X, Li G. Phenformin and ataxia-telangiectasia mutated inhibitors synergistically co-suppress liver cancer cell growth by damaging mitochondria. FEBS Open Bio. 2021 May;11(5):1440-1451. doi: 10.1002/2211-5463.13152. Epub 2021 Apr 03. PMID: 33742560; PMCID: PMC8091576.
Copy Download .nbib Format: NLM
A novel perfusion culture system for screening mitochondrial toxicity in primary mouse hepatocytes.

The Journal of toxicological sciences

Yamamoto C, Takemura A, Ishii S, Doi A, Saito I, Yamada H, Sakai Y, Matsunaga T, Ito K.
PMID: 34987137
J Toxicol Sci. 2022;47(1):13-18. doi: 10.2131/jts.47.13.

The liver microphysiological system (MPS) model is an in-vitro culture method that mimics physiological blood flow, which enhances basal cellular functions. However, the liver MPS model has not been tested in the preclinical stage because of its obscure utility....

Cite
Yamamoto C, Takemura A, Ishii S, et al. A novel perfusion culture system for screening mitochondrial toxicity in primary mouse hepatocytes. J Toxicol Sci. 2022;47(1):13-18doi: 10.2131/jts.47.13.
Yamamoto, C., Takemura, A., Ishii, S., Doi, A., Saito, I., Yamada, H., Sakai, Y., Matsunaga, T., & Ito, K. (2022). A novel perfusion culture system for screening mitochondrial toxicity in primary mouse hepatocytes. The Journal of toxicological sciences, 47(1), 13-18. https://doi.org/10.2131/jts.47.13
Yamamoto, Chika, et al. "A novel perfusion culture system for screening mitochondrial toxicity in primary mouse hepatocytes." The Journal of toxicological sciences vol. 47,1 (2022): 13-18. doi: https://doi.org/10.2131/jts.47.13
Yamamoto C, Takemura A, Ishii S, Doi A, Saito I, Yamada H, Sakai Y, Matsunaga T, Ito K. A novel perfusion culture system for screening mitochondrial toxicity in primary mouse hepatocytes. J Toxicol Sci. 2022;47(1):13-18. doi: 10.2131/jts.47.13. PMID: 34987137.
Copy Download .nbib Format: NLM
Bioassay of phenformin for possible carcinogenicity.

National Cancer Institute carcinogenesis technical report series

[No authors listed]
PMID: 12844191
Natl Cancer Inst Carcinog Tech Rep Ser. 1977 Jan;7:1-103.

A bioassay of the carcinogenicity of phenformin hydrochloride was conducted using Fischer 344 rats and B6C3F1 mice. The compound was administered in the diet for 78 weeks to groups of 35 animals of each species and sex, using concentrations...

Cite
Bioassay of phenformin for possible carcinogenicity. Natl Cancer Inst Carcinog Tech Rep Ser. 1977;7:1-103
(1977). Bioassay of phenformin for possible carcinogenicity. National Cancer Institute carcinogenesis technical report series, 71-103.
"Bioassay of phenformin for possible carcinogenicity." National Cancer Institute carcinogenesis technical report series vol. 7 (1977): 1-103.
Bioassay of phenformin for possible carcinogenicity. Natl Cancer Inst Carcinog Tech Rep Ser. 1977 Jan;7:1-103. PMID: 12844191.
Copy Download .nbib Format: NLM
Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds.

Oncology letters

El-Masry OS, Brown BL, Dobson PR.
PMID: 22740885
Oncol Lett. 2012 Jan;3(1):224-228. doi: 10.3892/ol.2011.458. Epub 2011 Oct 21.

Breast cancer remains a therapeutic challenge, and this has intensified the search for new drug targets. The AMP-activated protein kinase (AMPK) signalling pathway is emerging as having potential for intervention. We assessed the possible different effects of AMPK action...

Cite
El-Masry OS, Brown BL, Dobson PR. Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds. Oncol Lett. 2011;3(1):224-228doi: 10.3892/ol.2011.458.
El-Masry, O. S., Brown, B. L., & Dobson, P. R. (2012). Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds. Oncology letters, 3(1), 224-228. https://doi.org/10.3892/ol.2011.458
El-Masry, Omar S, et al. "Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds." Oncology letters vol. 3,1 (2012): 224-228. doi: https://doi.org/10.3892/ol.2011.458
El-Masry OS, Brown BL, Dobson PR. Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds. Oncol Lett. 2012 Jan;3(1):224-228. doi: 10.3892/ol.2011.458. Epub 2011 Oct 21. PMID: 22740885; PMCID: PMC3362498.
Copy Download .nbib Format: NLM
A supercritical fluid chromatography/tandem mass spectrometry method for the simultaneous quantification of metformin and gliclazide in human plasma.

Indian journal of pharmaceutical sciences

Agrawal YK, Gogoi PJ, Manna K, Bhatt HG, Jain VK.
PMID: 20582190
Indian J Pharm Sci. 2010 Jan;72(1):50-7. doi: 10.4103/0250-474X.62231.

Present study reports the development and validation of a simultaneous estimation of metformin and gliclazide in human plasma using supercritical fluid chromatography followed by tandem mass spectrometry. Acetonitrile:water (80:20) mixture was used as a mobile phase along with liquid...

Cite
Agrawal YK, Gogoi PJ, Manna K, et al. A supercritical fluid chromatography/tandem mass spectrometry method for the simultaneous quantification of metformin and gliclazide in human plasma. Indian J Pharm Sci. 2010;72(1):50-7doi: 10.4103/0250-474X.62231.
Agrawal, Y. K., Gogoi, P. J., Manna, K., Bhatt, H. G., & Jain, V. K. (2010). A supercritical fluid chromatography/tandem mass spectrometry method for the simultaneous quantification of metformin and gliclazide in human plasma. Indian journal of pharmaceutical sciences, 72(1), 50-7. https://doi.org/10.4103/0250-474X.62231
Agrawal, Y K, et al. "A supercritical fluid chromatography/tandem mass spectrometry method for the simultaneous quantification of metformin and gliclazide in human plasma." Indian journal of pharmaceutical sciences vol. 72,1 (2010): 50-7. doi: https://doi.org/10.4103/0250-474X.62231
Agrawal YK, Gogoi PJ, Manna K, Bhatt HG, Jain VK. A supercritical fluid chromatography/tandem mass spectrometry method for the simultaneous quantification of metformin and gliclazide in human plasma. Indian J Pharm Sci. 2010 Jan;72(1):50-7. doi: 10.4103/0250-474X.62231. PMID: 20582190; PMCID: PMC2883227.
Copy Download .nbib Format: NLM
Drugs and colon cancer.

Pharmacoepidemiology and drug safety

Friedman GD, Coates AO, Potter JD, Slattery ML.
PMID: 15073733
Pharmacoepidemiol Drug Saf. 1998 Mar;7(2):99-106. doi: 10.1002/(SICI)1099-1557(199803/04)7:2<99::AID-PDS320>3.0.CO;2-0.

In a case-control study of colon cancer conducted in three geographic regions of the United States, 1993 case subjects and 2410 control subjects were interviewed. In addition to queries regarding other known or suspected risk factors, subjects were asked...

Cite
Friedman GD, Coates AO, Potter JD, et al. Drugs and colon cancer. Pharmacoepidemiol Drug Saf. 1998;7(2):99-106doi: 10.1002/(SICI)1099-1557(199803/04)7:2<99::AID-PDS320>3.0.CO;2-0.
Friedman, G. D., Coates, A. O., Potter, J. D., & Slattery, M. L. (1998). Drugs and colon cancer. Pharmacoepidemiology and drug safety, 7(2), 99-106. https://doi.org/10.1002/(SICI)1099-1557(199803/04)7:2<99::AID-PDS320>3.0.CO;2-0
Friedman, G D, et al. "Drugs and colon cancer." Pharmacoepidemiology and drug safety vol. 7,2 (1998): 99-106. doi: https://doi.org/10.1002/(SICI)1099-1557(199803/04)7:2<99::AID-PDS320>3.0.CO;2-0
Friedman GD, Coates AO, Potter JD, Slattery ML. Drugs and colon cancer. Pharmacoepidemiol Drug Saf. 1998 Mar;7(2):99-106. doi: 10.1002/(SICI)1099-1557(199803/04)7:2<99::AID-PDS320>3.0.CO;2-0. PMID: 15073733.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 65 entries